The overall goal of the NCTN Program is to conduct definitive, randomized, late phase clinical treatment trials and advanced imaging trials across a broad range of diseases and diverse patient populations, as well as development efforts preliminary to those trials, as part of the NCI's overall clinical research program for adults and children with cancer. The mission of the NCIC CTG is to develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease. The overlaps of these goals create a rationale for a Canadian Collaborating Clinical Trials Network. This rationale is further supported by similar societal expectations by Canadians and Americans for improved health outcomes and similar respective strategic priorities of NCIC CTG and the NCTN that recognize that new understandings of the molecular basis of carcinogenesis have the potential to advance health care delivery, including through improved therapeutic targeting of the cancer cell and better identification of therapies for individual patients. The specific objectives of NCIC CTG to collaborate with NCI/CTEP and US-based groups, through its newly-formed National Clinical Trials Network Program, to develop new Intergroup trials under NCIC CTG leadership and to ensure more rapid accrual to trials led by US-based groups, to enhance the scientific content of these trials through evaluation of additional endpoints and to contribute to new understandings of clinical trial methodology and analysis.
This aim i s facilitated by NCIC CTG's unique information technology supports and understandings of the Canadian regulatory environment.
The aims of this application are to facilitate Canadian leadership of NCTN trials that represent value from the perspective of expenditure of U.S. federal dollars and to conduct U.S.-led NCTN trials in Canada.
The NCIC CTG is the only adult cooperative oncology group based in Canada that has a national membership and is committed to assessing all modalities of therapy across the spectrum of different types of cancer. The Group's activities have included leadership of and participation in large randomized phase clinical trials conducted in the US and Canada by both the NCIC CTG and US-based cooperative groups.
|Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121|
|Walter, Roland B; Michaelis, Laura C; Othus, Megan et al. (2018) Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. Am J Hematol 93:E49-E52|
|Galanis, Evanthia; Anderson, S Keith; Miller, C Ryan et al. (2018) Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Neuro Oncol 20:546-556|
|Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718|
|Phipps, Amanda I; Shi, Qian; Zemla, Tyler J et al. (2018) Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiol Biomarkers Prev 27:696-703|
|Ristau, Benjamin T; Manola, Judi; Haas, Naomi B et al. (2018) Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol 199:53-59|
|Roberge, David; Brown, Paul D; Whitton, Anthony et al. (2018) The Future Is Now-Prospective Study of Radiosurgery for More Than 4 Brain Metastases to Start in 2018! Front Oncol 8:380|
|Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571|
|Wagner, Lynne I; Zhao, Fengmin; Goss, Paul E et al. (2018) Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG Breast Cancer Res Treat 169:537-548|
|van den Bent, Martin J; Baumert, Brigitta; Erridge, Sara C et al. (2017) Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 390:1645-1653|
Showing the most recent 10 out of 26 publications